190 related articles for article (PubMed ID: 27131748)
21. The role of the chemical biology core facility at EMBL: a vision for a European roadmap.
Lewis JD
ACS Chem Biol; 2007 Jan; 2(1):21-3. PubMed ID: 17243779
[No Abstract] [Full Text] [Related]
22. An interview with Richard M. Eglen, Ph.D.
Eglen RM
Assay Drug Dev Technol; 2006 Oct; 4(5):503-9. PubMed ID: 17115921
[No Abstract] [Full Text] [Related]
23. Timely synthetic support for medicinal chemists.
Potoski J
Drug Discov Today; 2005 Jan; 10(2):115-20. PubMed ID: 15718160
[TBL] [Abstract][Full Text] [Related]
24. Toward biosimilar monoclonal antibodies.
Schneider CK; Kalinke U
Nat Biotechnol; 2008 Sep; 26(9):985-90. PubMed ID: 18779806
[No Abstract] [Full Text] [Related]
25. An industrial perspective on the design and development of medicines for older patients.
Page S; Coupe A; Barrett A
Int J Pharm; 2016 Oct; 512(2):352-354. PubMed ID: 27001530
[TBL] [Abstract][Full Text] [Related]
26. New advances in drug discovery.
Macphee C
Expert Opin Investig Drugs; 2004 Sep; 13(9):1213-5. PubMed ID: 15330753
[TBL] [Abstract][Full Text] [Related]
27. 19th International Symposium on Medicinal Chemistry.
Baker M
ACS Chem Biol; 2006 Oct; 1(9):549-53. PubMed ID: 17168546
[TBL] [Abstract][Full Text] [Related]
28. Drug discovery alliances.
Jones A; Clifford L
Nat Rev Drug Discov; 2005 Oct; 4(10):807-8. PubMed ID: 16237845
[No Abstract] [Full Text] [Related]
29. Its all about delivery: interview with M. N. V. Ravi Kumar.
Kumar MN
Ther Deliv; 2015; 6(10):1135-7. PubMed ID: 26446378
[TBL] [Abstract][Full Text] [Related]
30. Development trends for therapeutic antibody fragments.
Nelson AL; Reichert JM
Nat Biotechnol; 2009 Apr; 27(4):331-7. PubMed ID: 19352366
[No Abstract] [Full Text] [Related]
31. The future of discovery chemistry: quo vadis? Academic to industrial--the maturation of medicinal chemistry to chemical biology.
Hoffmann T; Bishop C
Drug Discov Today; 2010 Apr; 15(7-8):260-4. PubMed ID: 20149893
[TBL] [Abstract][Full Text] [Related]
32. The role of the medicinal chemist in drug discovery--then and now.
Lombardino JG; Lowe JA
Nat Rev Drug Discov; 2004 Oct; 3(10):853-62. PubMed ID: 15459676
[TBL] [Abstract][Full Text] [Related]
33. Chemical genomics versus orthodox drug development.
Szymkowski DE
Drug Discov Today; 2003 Feb; 8(4):157-9. PubMed ID: 12581708
[No Abstract] [Full Text] [Related]
34. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
35. Fewer jobs available for new PhDs.
Ann Neurol; 2012 Mar; 71(3):A8. PubMed ID: 22451215
[No Abstract] [Full Text] [Related]
36. Facts, figures and trends in lead generation.
Deprez-Poulain R; Deprez B
Curr Top Med Chem; 2004; 4(6):569-80. PubMed ID: 14965294
[TBL] [Abstract][Full Text] [Related]
37. [Chemical drug development].
Castro B
Ann Pharm Fr; 2002 May; 60(3):147-9. PubMed ID: 12050592
[No Abstract] [Full Text] [Related]
38. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
Fitzgerald GA
Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
[TBL] [Abstract][Full Text] [Related]
39. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
40. The end of the beginning?
Nat Rev Drug Discov; 2006 Sep; 5(9):705. PubMed ID: 17001798
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
